$0.21 EPS Expected for LeMaitre Vascular Inc (LMAT) This Quarter

Brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to post $0.21 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular posted earnings per share of $0.43 during the same quarter last year, which indicates a negative year over year growth rate of 51.2%. The company is expected to report its next quarterly earnings results on Thursday, July 25th.

On average, analysts expect that LeMaitre Vascular will report full year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.82 to $0.84. For the next fiscal year, analysts anticipate that the company will report earnings of $0.92 per share, with EPS estimates ranging from $0.89 to $0.95. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $28.48 million during the quarter, compared to the consensus estimate of $27.94 million. LeMaitre Vascular had a return on equity of 16.76% and a net margin of 20.92%. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the business posted $0.19 EPS.

LMAT has been the topic of several analyst reports. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Thursday, February 7th. Lake Street Capital raised their target price on LeMaitre Vascular to $27.00 and gave the company a “hold” rating in a research report on Wednesday, February 20th. ValuEngine upgraded LeMaitre Vascular from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Roth Capital restated a “neutral” rating on shares of LeMaitre Vascular in a research report on Thursday, February 21st. Finally, BidaskClub upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. LeMaitre Vascular currently has an average rating of “Hold” and a consensus target price of $31.00.

Several hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of LeMaitre Vascular by 2.7% during the third quarter. Bank of New York Mellon Corp now owns 253,149 shares of the medical instruments supplier’s stock valued at $9,807,000 after acquiring an additional 6,705 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of LeMaitre Vascular by 7.4% during the third quarter. Teachers Advisors LLC now owns 31,470 shares of the medical instruments supplier’s stock valued at $1,219,000 after acquiring an additional 2,162 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of LeMaitre Vascular by 11.0% during the third quarter. Legal & General Group Plc now owns 33,785 shares of the medical instruments supplier’s stock valued at $1,295,000 after acquiring an additional 3,360 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of LeMaitre Vascular by 5.8% during the third quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after acquiring an additional 66,427 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of LeMaitre Vascular by 99.1% during the fourth quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 554 shares in the last quarter. Institutional investors own 77.22% of the company’s stock.

Shares of NASDAQ LMAT traded down $0.13 during mid-day trading on Friday, hitting $25.80. The company had a trading volume of 1,376 shares, compared to its average volume of 81,941. The company has a market cap of $510.04 million, a price-to-earnings ratio of 30.81, a price-to-earnings-growth ratio of 2.65 and a beta of 1.17. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 6th. Stockholders of record on Wednesday, May 22nd will be given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: Return On Assets

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.